Booster dose reshapes SARS-CoV-2 RBD-specific B cell immunity in people living with HIV.

ABSTRACT:

Background

Long-term persistence of spike-specific memory B cells (MBC) upon mRNA SARS-CoV-2 vaccination remains poorly explored in people living with HIV (PLWH). We previously observed that the primary two-dose immunization elicited a B cell response quantitatively similar but phenotypically different compared to healthy participants (HC), with higher prevalence of CD27^-IgD^- double-negative cells and lower proportion of CD27⁺ Ig-switched MBC.

Methods

The PatoVac_COV longitudinal prospective single-centre study included 74 PLWH vaccinated with mRNA SARS-CoV-2 vaccines. Building upon our previous findings, blood samples were collected before and after the third and fourth doses, and two years after the first dose. PBMC were analysed for the RB

SUBMITTER: Polvere J 

PROVIDER: S-EPMC12661889 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature